CFTR and cystic fibrosis: It was surprising that 6 months treatment with ivacaftor in CF patients with the G551D mutation improved lung function, and reduced sweat chloride, indicating an effect on CFTR function, without an effect on pulmonary inflammation (Rowe et al., 2014).